Exosome Manufacture Based on the iCELLis® Bioreactor Platform

VivaZome Therapeutics is a privately-held Melbourne-based biotech company developing exosome therapeutics. Our approach is to use natural or native exosomes secreted by cells to treat disease. Exosome manufacture involves the separation and concentration of exosomes from cell culture supernatant.

VivaZome has identified two human cells types that produce high numbers of angiogenic exosomes suitable for treating a range of ischaemic diseases. The VivaZome preferred cells are adherent and similar to mesenchymal stem/stromal cells in their growth requirements. Accordingly, we evaluated Pall’s iCELLis Nano bioreactor to assess its suitability for supporting exosome manufacture.